Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
BTB (POZ) domain containing 19 is a member of the BTB/POZ domain protein family. The BTB domain is a protein-protein interaction motif found in various transcription factors and other intracellular proteins, often involved in transcriptional regulation and chromatin remodeling. BTBD19 has been implicated in transcriptional regulation and genome stability functions, mainly inferred from the general behavior of BTB domain proteins. Recent genomic analyses have highlighted BTBD19 as an epigenetically deregulated gene whose altered methylation status correlates with expression and prognosis in clear cell renal cell carcinoma, suggesting its utility as a prognostic biomarker but not as a direct drug target. BTBD19 is correctly named and classified. It is not a typical therapeutic target; rather, its main biomedical relevance resides in gene regulation and cancer prognosis biomarker potential, not as a receptor, enzyme, or other druggable entity.
None known; mechanisms of action for drugs targeting this molecule are not described, as BTBD19 is not currently a therapeutic target
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on BTB (POZ) domain containing 19 (BTBD19).